Sales & Earnings

Adcock saw its profits grow by 4.2% during FY 2024 despite a challenging economic environment.

Analysts posted wary notes about the prospects of South African pharmaceutical firm Aspen as its financial year came to an end, while management maintained confidence in the firm’s “solid results.”

India’s Glenmark is hoping that its proposed generic version of GlaxoSmithKline’s Flovent will benefit from a limited competition market, as it continues to plan a filing with the US Food and Drug Administration.

Swedish biosimilars player Xbrane spoke candidly about its recent launch of the company’s first product, the Stada-partnered Ximluci biosimilar to Lucentis in Europe, as it updated on the company’s ongoing hunt for a new US commercialization partner.

With Alvotech once again asking the US FDA to approve its AVT02 high-concentration interchangeable adalimumab candidate after multiple knockbacks, the company says that the opportunity has not passed as the story of Humira biosimilars is “still being written.”

Formycon delivered a strong H1, as its Lucentis biosimilar made significant strides in the US market. The company now anticipates the highest revenue in its history for 2023.

With around a month to go until Sandoz is expected to become a standalone company following its spinoff from parent Novartis, the firm has published additional financial information ahead of a shareholders meeting in mid-September.

After several lackluster quarters, Towa’s acquisition of Sunsho Pharmaceutical is finally paying off for the Japanese generics firm.

Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.

A US FDA tentative approval for Aurobindo’s dolutegravir combination generic for children should increase access under the PEPFAR program and aid sales. On a Q1 earnings call, renewed efforts to restructure Eugia, biosimilar launch plans and fallouts of oral drug shortages and damage to Pfizer’s US injectables warehouse were discussed.

The performance of its recently-launched Spiriva generic will be crucial for Lupin’s future performance, as it forecasts year-end exit margins in the high teens.

Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.

Management at ANI has upped its estimates for the second time this year after another impressive quarter, driven by Cortrophin gel and a strong generics performance.

Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.

Organon’s CEO Kevin Ali talked at length about the company’s launch of its Hadlima biosimilar version of Humira in the US during the company’s Q2 earnings call, following recent news it was looking to file for an interchangeability designation.

A sharp upswing in the US business, an alliance with Mark Cuban’s venture and a buoyant outlook in markets like China augur well for Dr Reddy’s. Can the company sustain momentum for the rest of year?